Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3b oral edaravone dosing regimen study in amyotrophic lateral sclerosis
2019-004256-11Phase 3Completed
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing Oral edaravone once daily with Oral edaravone on/off regimen including placebo (2 arms). Primary endpoint: Change in ALSFRS-R score from baseline to Week 48 of treatment. Started Nov 2020; status: completed.
02
Drugs
edaravone
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on 2019-004256-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004256-11.